Shkreli's Brazen Defiance May Lead To Harsher Sentence
Public statements from former Turing Pharmaceuticals and Retrophin CEO Martin Shkreli deriding the prosecution's securities fraud case against him may come back to bite him at sentencing, legal experts said Monday....To view the full article, register now.
Already a subscriber? Click here to view full article